Small molecule · developed by Lipocine
LPCN 1148 is an oral capsule containing an ester prodrug of bioidentical testosterone, designed for absorption through the intestinal lymphatics. It is studied in liver cirrhosis and sarcopenia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04874350 | Phase 2 | Liver Cirrhosis | Completed | LPCN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Liver CirrhosisSarcopenia
Updated Oct 18, 2026. Something wrong or missing? Report it on the LPCN page.
See LPCN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LPCN catalysts and pipeline →